Biosortia Microbiomics

Biosartia Microbiomics invites investors to evaluate their lead oral weight-loss asset—a novel GLP-1R positive allosteric modulator (PAM) with selective polypharmacology —and to explore how their deep access and prediction engine can fill Pharma's pipelines with validated, nature-derived candidates that synthetic libraries simply cannot provide.